Materials and methods for diagnosis, prognosis, monitoring of recurrence, and assessment of therapeutic/prophylactic treatment of pancreatobiliary cancer

摘要

A method of detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract or inferring an increased risk thereof, comprising obtaining a sample of pancreatobiliary cells from a patient with a set of detectably labeled probes comprising a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), a locus-specific probe for EGFR (epidermal growth factor receptor), a locus-specific probe for MYC, and a locus-specific probe for P16 under hybridization conditions and determining the presence of chromosomal abnormalities; a set of probes comprising a locus-specific probe for MCL1, a locus-specific probe for EGFR, a locus-specific probe for MYC, and a locus-specific probe for P16; and a kit comprising the set of probes and instructions for detecting high-grade dysplasia, pancreatobiliary cancer, or metastatic cancer to the pancreatobiliary tract, or inferring an increased risk thereof, in a patient.

主权项

1. A set of detectably labeled probes for detecting pancreatobiliary cancer in a patient, wherein the set of detectably labeled probes consists of a locus-specific probe for MCL1 (myeloid cell leukemia sequence 1), which hybridizes to q21 on human chromosome 1, a locus-specific probe for EGFR (epidermal growth factor receptor), which hybridizes to p12 on human chromosome 7, a locus-specific probe for MYC, which hybridizes to q24 on human chromosome 8, and a locus-specific probe for P16, which hybridizes to p21 on human chromosome 9, and wherein each probe is detectably labeled with a distinct fluorophore.